In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.
NIH researchers got tantalizingly close to long-term engraftment at levels that could provide a clinical benefit in gene therapy applications.
In Cell this week: strategies for targeting leukemia with MLL translocations, new Perturb-seq approach, and more.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
The Silicon Valley startup has launched with a proprietary automation platform, and counts CRISPR researcher Jennifer Doudna among its new investors.
The biggest biology stories of the year include the Zika virus, CRISPR, and more, according to Wired.
Researchers uncover anti-CRISPR proteins that could help genetic engineering to be safer.
Derived from Listeria phages, the study found four new proteins that inhibit Cas9 activity, two of which also work in E. coli and engineered human cells.
A writer argues that gene editing might eliminate variants that are beneficial in some circumstances, the Telegraph reports.
In Nature this week: DNA methylation patters can uncover people at increased risk of diabetes, and more.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.